- Dr. Barry K. Herman appointed SVP, Head of Medical Affairs
- Paul J. Casanova appointed SVP, Sales
GEORGE TOWN, Cayman Islands--(BUSINESS WIRE)--Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and the global leader in the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced that its U.S. affiliate, Ironshore Pharmaceuticals Inc. has appointed Dr. Barry K. Herman as Senior Vice President, Head of Medical Affairs and Mr. Paul J. Casanova as Senior Vice President, Sales. The additions to the Executive Management Team reflect the continued expansion of the Company’s medical and commercial infrastructure in anticipation of the pending launch of HLD200 (delayed-release and extended-release methylphenidate, dosed at bedtime), Ironshore’s investigational drug candidate for the treatment of ADHD. A New Drug Application is currently pending before the U.S. Food and Drug Administration.
“The appointment of these experienced executives with well-established and documented expertise to critical roles within our organization is a clear reflection of our ongoing ability to attract exceptional talent as we build-out an innovative commercial infrastructure using best-in-class practices,” said Craig C. Lewis, President of Ironshore Pharmaceuticals Inc.
Commenting on his appointment, Dr. Barry K. Herman stated, “As a Board-Certified psychiatrist who has dedicated his career to improving the lives of patients, I am excited to be at an organization like Ironshore that is equally committed to doing things the right way and to raising awareness regarding the importance of the early morning routine for families impacted by ADHD.”
Dr. Randy Sallee, Chief Medical Officer of Ironshore Pharmaceuticals Inc. and author of over 100 journal articles on ADHD, added, “The growing sense of awareness among members of the medical community and the eagerness of my colleagues to discuss the topic of challenges during the morning routine is a testament to the fact that this has been a long-suffering problem for patients with ADHD and their caregivers, and the physicians who treat those patients.”
Mr. Paul J. Casanova, Senior Vice President, Sales stated, “Having spent nearly a decade specializing in the ADHD market, I have never been more optimistic about the potential to meaningfully improve patient outcomes. The team at Ironshore is extraordinary, and the Company is starting to be recognized as the leader in ADHD that it is.”
Paul J. Casanova
Mr. Casanova brings more than three decades of sales leadership across the pharmaceutical sector with extensive experience launching blockbuster products, including within the ADHD category. Paul joins Ironshore from Shire Pharmaceuticals where he led a field-based Sales Leadership Team of 12 regional directors and more than 110 sales specialists for the company’s ADHD portfolio, generating annual revenues of approximately $600 million. He recently earned Shire’s CEO Award for exceptional performance. Earlier in his career, Paul served for 16 years at Pfizer Pharmaceuticals; initially as a Professional Healthcare Representative and later as CNS Specialty District Manager. He received his Master of Business Administration from the University of New Haven and served as a Sergeant for the United States Marine Corps Reserve.
Barry K. Herman, M.D., M.M.M.
Dr. Barry Herman is a dual Board Certified Psychiatrist (Adult Psychiatry and Child & Adolescent Psychiatry) with 16 years of medical affairs experience in the pharmaceutical industry. He was most recently Global Franchise Medical Lead, Senior Medical Director, Global Medical Affairs, Neuroscience for Shire Pharmaceuticals.
Dr. Herman is a Distinguished Life Fellow of the American Psychiatric Association and a Distinguished Fellow of the American Academy of Child and Adolescent Psychiatry; a Vanguard Fellow Emeritus of the American College of Physician Executives; and a Lifetime Member of the American Medical Association. The author of over 100 scientific abstracts and publications, Dr. Herman is the recipient of the 2017 American Psychiatric Association Award in Administrative Psychiatry.
Dr. Herman received his Medical Degree from Tufts University School of Medicine, and completed a Fellowship in Child and Adolescent Psychiatry at Stanford University School of Medicine. He received a Master of Medical Management (M.M.M.) degree from Tulane University School of Public Health and Tropical Medicine.
About Ironshore Pharmaceuticals & Development, Inc.
Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., is a pharmaceutical company that is leveraging its proprietary drug delivery platform, DELEXIS®, to optimize the delivery of previously approved drug products.
Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer and capital networks, and market intelligence to high-impact, Ontario, Canada-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies. For more information, visit Highlandtherapeutics.com
Forward-Looking Statements
This press release contains forward-looking information, which reflects Ironshore’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Ironshore’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Ironshore assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
